Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
2010 1
2011 1
2014 1
2015 2
2016 3
2017 4
2018 2
2019 3
2020 6
2021 10
2022 6
2023 5
2024 6
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP. Abramson JS, et al. Among authors: gregory gp. Lancet. 2024 Nov 16;404(10466):1940-1954. doi: 10.1016/S0140-6736(24)01774-4. Lancet. 2024. PMID: 39550172 Clinical Trial.
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, Gregory GP, Yoon DH, Shadman M, Fay K, Yoon SS, Panizo C, Flinn I, Johnston A, Bosch F, Sehn LH, Wei MC, Yin S, To I, Li CC, Huang H, Kwan A, Penuel E, Budde LE. Bartlett NL, et al. Among authors: gregory gp. Blood Adv. 2023 Sep 12;7(17):4926-4935. doi: 10.1182/bloodadvances.2022009260. Blood Adv. 2023. PMID: 37067952 Free PMC article.
Burkitt lymphoma: click here to add to CAR-T?
Hawkes EA, Gregory GP. Hawkes EA, et al. Among authors: gregory gp. Blood. 2025 Jun 5;145(23):2678-2680. doi: 10.1182/blood.2025028549. Blood. 2025. PMID: 40471624 No abstract available.
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
Matasar M, Bartlett NL, Shadman M, Budde LE, Flinn I, Gregory GP, Kim WS, Hess G, El-Sharkawi D, Diefenbach CS, Huang H, To I, Parreira J, Wu M, Kwan A, Assouline S. Matasar M, et al. Among authors: gregory gp. Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):240-253. doi: 10.1016/j.clml.2023.12.005. Epub 2023 Dec 12. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38195322 Free article. Clinical Trial.
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.
Tatarczuch M, Lewis KL, Gunjur A, Shaw B, Poon LM, Paul E, Ku M, Wong M, Ai S, Beekman A, Ciaccio PRD, Krigstein M, Wight J, Coombes C, Gilbertson M, Tey A, Shortt J, Nagarajan C, Talaulikar D, Hamad N, Ratnasingam S, Ho SJ, Cochrane T, Hawkes EA, Cheah CY, Opat S, Gregory GP. Tatarczuch M, et al. Among authors: gregory gp. EJHaem. 2024 Jun 21;5(4):709-720. doi: 10.1002/jha2.951. eCollection 2024 Aug. EJHaem. 2024. PMID: 39157596 Free PMC article.
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma.
Oh DH, Ma X, Hogg SJ, He J, Kearney C, Brasacchio D, Susanto O, Maher B, Jennings IG, Newbold A, Fraser P, Gruber E, Kats LM, Gregory GP, Johnstone RW, Thompson PE, Shortt J. Oh DH, et al. Among authors: gregory gp. Proc Natl Acad Sci U S A. 2023 Sep 5;120(36):e2306414120. doi: 10.1073/pnas.2306414120. Epub 2023 Aug 29. Proc Natl Acad Sci U S A. 2023. PMID: 37643213 Free PMC article.
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.
Gregory GP, Kumar S, Wang D, Mahadevan D, Walker P, Wagner-Johnston N, Escobar C, Bannerji R, Bhutani D, Chang J, Hernandez-Ilizaliturri FJ, Klein A, Pagel JM, Rybka W, Yee AJ, Mohrbacher A, Huang M, Farooqui M, Marinello P, Quach H. Gregory GP, et al. Blood Adv. 2022 Feb 22;6(4):1232-1242. doi: 10.1182/bloodadvances.2021005872. Blood Adv. 2022. PMID: 34972202 Free PMC article. Clinical Trial.
50 results